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Effect of Methamphetamine on Gingival Fibroblast Production of Matrix
Metalloproteinase (MMP)-2 and -9 and Tissue Inhibitor of Metalloproteinase
(TIMP)-1 and -2 In Vitro
Abstract
Methamphetamine (METH) abuse is associated with "METH mouth" characterized by rampant caries and
periodontitis. Matrix metalloproteinases (MMPs) produced by gingival fibroblasts degrade the
extracellular matrix (ECM) and play an important role in periodontitis and oral cancer metastasis. There is
no information on effects of METH on fibroblast MMP production, or its role in periodontitis or tumor
metastasis.
Objective: Determine effect of METH on gingival fibroblast MMP production and activity.
Methods: A human gingival fibroblast cell line was used. METH cytotoxicity was determined by measuring
its effects on activity of a mitochondrial enzyme. Cells were cultured ± METH (1x10-6- ≥ 1x10-3M);
MMP-2, MMP-9, TIMP-1,TIMP-2 and MMP:TIMP complexes in cell supernatants were measured by ELISA.
MMP-2 activity was measured using the MMP-2 Biotrak Activity Assay System. Data were analyzed using
ANOVA and Scheffe’s F procedure for post hoc comparisons.
Results: There was no significant cytotoxicity of METH at concentrations ≤ 1mM. METH > 1mM caused
complete loss of viability. MMP-2, TIMP-1, -2 and MMP-2:TIMP complexes were produced constitutively;
MMP-9 and MMP-9:TIMP complexes were not expressed. Approximately 25% of MMP-2 was complexed
with TIMP-1 or TIMP-2. METH had no significant effect on any molecules expressed constitutively or on
complexed MMP-2, and it did not induce MMP-9 or MMP-9:TIMP complexes. 1x10-5 M METH increased
total MMP-2 activity (p = 0.01) and APMA-activated MMP-2 activity attributable to pro-MMP-2 (p = 0.03).
METH had no effect on endogenous active MMP-2. Using pro-MMP-2 (standard from MMP-2 activity kit)
treated with METH ± p-aminophenylmercuric acetate (APMA) and assayed for activity, METH directly
activated MMP-2 and enhanced APMA activation of free pro-MMP-2.
Conclusions: METH may affect MMP-2 post-transcriptionally, increasing activity/activation of pro-MMP-2,
rather than affecting protein levels.

Document Type
Thesis

Degree Name
Master of Dental Science (MDS)

Program
Periodontology

Research Advisor
David A. Tipton, D.D.S., Ph.D.

Keywords
Fibroblast, Matrix Metalloproteinase, Methamphetamine

Subject Categories
Dentistry | Medicine and Health Sciences | Periodontics and Periodontology
This thesis is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/84

Effect of Methamphetamine on Gingival Fibroblast Production of Matrix
Metalloproteinase (MMP)-2 and -9 and Tissue Inhibitor of Metalloproteinase
(TIMP)-1 and -2 In Vitro

A Thesis
Presented for
The Graduate Studies Council
The University of Tennessee
Health Science Center

In Partial Fulfillment
Of the Requirements for the Degree
Master of Dental Science
From The University of Tennessee

By
Owais Ali Farooqi
May 2009

Copyright © 2009 by Owais Ali Farooqi
All rights reserved

ii

ACKNOWLEDGEMENTS
This research project would have been impossible without help and support of my
research mentor Dr. David A. Tipton. I would like to thank my committee members Drs.
Pradeep Adatrow, Jegdish Babu, Mustafa Dabbous and Swati Rawal who gave their
valuable input and encouraged me throughout this project. I must also express my
gratitude to UT Alumni who contribute to University of Tennessee College of Dentistry
Alumni Endowment Fund, which funded this research endeavor.

iii

ABSTRACT
Methamphetamine (METH) abuse is associated with "METH mouth"
characterized by rampant caries and periodontitis. Matrix metalloproteinases (MMPs)
produced by gingival fibroblasts degrade the extracellular matrix (ECM) and play an
important role in periodontitis and oral cancer metastasis. There is no information on
effects of METH on fibroblast MMP production, or its role in periodontitis or tumor
metastasis.
Objective: Determine effect of METH on gingival fibroblast MMP production
and activity.
Methods: A human gingival fibroblast cell line was used. METH cytotoxicity was
determined by measuring its effects on activity of a mitochondrial enzyme. Cells were
cultured ± METH (1x10-6- ≥ 1x10-3M); MMP-2, MMP-9, TIMP-1,TIMP-2 and
MMP:TIMP complexes in cell supernatants were measured by ELISA. MMP-2 activity
was measured using the MMP-2 Biotrak Activity Assay System. Data were analyzed
using ANOVA and Scheffe’s F procedure for post hoc comparisons.
Results: There was no significant cytotoxicity of METH at concentrations ≤
1mM. METH > 1mM caused complete loss of viability. MMP-2, TIMP-1, -2 and MMP2:TIMP complexes were produced constitutively; MMP-9 and MMP-9:TIMP complexes
were not expressed. Approximately 25% of MMP-2 was complexed with TIMP-1 or
TIMP-2. METH had no significant effect on any molecules expressed constitutively or on
complexed MMP-2, and it did not induce MMP-9 or MMP-9:TIMP complexes. 1x10-5 M
METH increased total MMP-2 activity (p = 0.01) and APMA-activated MMP-2 activity
attributable to pro-MMP-2 (p = 0.03). METH had no effect on endogenous active MMP2. Using pro-MMP-2 (standard from MMP-2 activity kit) treated with METH ± paminophenylmercuric acetate (APMA) and assayed for activity, METH directly
activated MMP-2 and enhanced APMA activation of free pro-MMP-2.
Conclusions: METH may affect MMP-2 post-transcriptionally, increasing
activity/activation of pro-MMP-2, rather than affecting protein levels.
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CHAPTER 1. INTRODUCTION AND BACKGROUND
Methamphetamine (METH) is a widely abused psychostimulant. Initially
synthesized in 1919 during World War I, the drug was prescribed for many soldiers
because of its stimulatory and performance-enhancing properties.1 It was not until 1959,
that the Food and Drug Administration (FDA) banned amphetamine-based inhalers
because of their potential for abuse. Currently the prevalence of METH use is estimated
at 35 million people worldwide and 10.4 million people in the United States.2 The
number of young people who are abusing METH is astonishing. The 2003 National
Survey on Drug Use and Health reported that 12.3 million Americans age 12 years or
older have used METH at least once.3 A survey conducted by the Centers for Disease
Control and Prevention found that approximately 1 in 10 high-school students had used
METH.4
METH and other amphetamine analogues are synthesized pharmcologically, by
attaching a substituent (methoxy, methyl, halogen, or sulfur) to different positions on the
phenyl ring of amphetamine.5 Amphetamines/METH have been used to treat depression,
attention deficit disorder, narcolepsy and to promote weight loss.6 The federal Drug
Enforcement Administration (DEA) currently classifies pharmaceutical-grade METH as a
Schedule II stimulant drug. Some pharmaceutical products containing amphetamines
approved for marketing include dextroamphetamine sulfate and a combination of
dextroamphetamine and amphetamine salts. Methylphenidate hydrochloride is a
piperidine derivative and is structurally similar to amphetamine; it therefore shares the
same pharmacologic properties. The abused form of this drug’s analogues include
methylenedioxyMETH (MDMA, ecstasy), methylenedioxyamphetamine (MDA, the love
pill), methylenedioxyethamphetamine (MDEA, Eve), and nonpharmaceutical grade
METH (ice, crystal meth). These drug analogues cause hyperactivity, euphoria,
talkativeness, hyperalertness, decreased appetite and increased physical and sexual
endurance.3 Not infrequently, mild toxicity is seen in people who abuse this drug. This is
characterized by headache, irritability, hypertension, headache, tachycardia, mydriasis,
tremor, hyperpyrexia, and hyperreflexia.7 Overdose can lead to confusion, diaphoresis,
palpitations, nausea, vomiting, hallucinations, convulsions, and coma.8,9,10,11 A method to
treat acute overdose, at least theoretically, is acidification of the urine to increase
elimination. This generally is not recommended due to risk of a weak base such as
METH becoming ionized in an acidic environment potentially causing rhabdomyolysis
and renal failure.12 METH is an extremely addictive and a potent stimulant of the central
nervous system, causing a release of norepinephrine and dopamine at the synaptic cleft
while blocking their reuptake.13 This depletes neurotransmitters and may contribute to
rapid tolerance and withdrawal symptoms. METH, structurally similar to epinephrine,
increases both systolic and diastolic blood pressures, which is usually accompanied by
reflex bradycardia.14
During a ―binge‖, one chronic METH user can consume 8–12 g of METH in one
day.9 METH can be snorted, smoked, swallowed, and injected. After oral administration,
the time to maximum plasma concentration (tmax) is two to three hours, although the
1

drug’s effects can be felt in as little as 20 minutes.15 METH users typically progress to
snorting, smoking, or injecting the drug to decrease the onset time; the tmax for injected,
snorted, and smoked METH is 2–4 minutes (described as the ―rush‖).16 METH is
metabolized primarily by the liver. The drug’s oxidation and glucuronidation results in a
active metabolite (amphetamine) and two inactive metabolites (norephedrine and phydroxynorephedrine). The elimination half-life (t½) of METH varies widely, depending
on urine pH. At pH 6–8, the t½ is approximately 12 hours and is relatively constant.14
Several case reports have been published on the effects of METH on oral tissues.
The clinical picture of "METH mouth" is one of rampant caries, xerostomia and teeth
with hopeless prognoses. Several factors contribute to these conditions. METH users are
hyperactive and rarely stop to eat or drink anything during times of acute drug use,
leading to generalized dehydration. Rather than drink water, METH users report craving
sugar and typically drink large quantities of non-diet, caffeine-rich soft drinks; MountainDew is commonly mentioned as a beverage of choice.17 METH also increases
sympathetic activity in the central nervous system, reducing saliva secretion by
stimulation of inhibitory α2 receptors resulting in reductions in unstimulated salivary
flow. What little saliva is produced is high in protein, thereby increasing the patient’s
sensation of oral dryness.18
METH abusers are frequently seen with rampant caries due to absence of
protective effects of saliva. Typically the cervical areas of both maxillary and mandibular
teeth are involved and lead to gross caries involvement of the entire tooth. However,
METH-associated caries progresses slowly as compared to other forms of caries caused
by drug- or postradiation-induced xerostomia.11 METH itself is acidic due to its chemical
formulation and therefore when smoked, the enamel breakdown could possibly occur.
However a study by Navarro et al. showed that high levels of MDMA detected in the
saliva accounted for only a small decrease in salivary pH, from 7.4 to 6.9. Because the
critical pH at which enamel demmineralizes is 5.5, the pH change caused by MDMA
does not significantly contribute to caries formation.19 METH causes restlessness,
anxiety, irritability, fatigue, and dysphoria. Tooth wear (bruxism) is very common in
these patients.20 During times of acute use, users tend to grind and clench their jaws,
further contributing to tooth wear.21 While a typical pattern of gross caries is often seen in
METH user, these patients can also exhibit significant gingival and periodontal
inflammation and destruction (Figure 1).
In periodontal tissue destruction as well as metastasis of oral cancer, a family of
zinc-dependent endopeptidases called matrix metalloproteinases (MMPs) are suggested
to play an important role.22,23 Inflammation of the periodontal tissues leads to connective
tissue degradation and tooth loss. Analysis of gingival crevicular fluid has shown the
presence of MMPs such as collagenase and gelatinase that, in the acute stages of
periodontitis, come mainly from polymorphonuclear leukocytes. These active forms of
these enzymes in gingival crevicular fluid or mouthrinse samples correlate with tissue
destruction and, therefore, provide a sensitive method to demonstrate disease activity.24
MMPs are able to degrade the components of periodontal extracellular matrix (ECM) and
fall into three major groups: the interstitial collagenases, the gelatinases and
2

Figure 1. Clinical Intra-oral Picture of METH User.
Reprinted with permission. Wagner S. Methamphetamine use and oral health.
http://www.ada.org/public/topics/methmouth.asp. (accessed 2009 March 12)25
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the stromelysins. The interstitial collagenases (MMP-1, -8 and -13) cleave interstitial
collagens. The gelatinases (MMP-2 and -9) degrade types IV, V, VII, X and XI collagens
as well as fibronectin, elastases and aggrecan. The gelatinases act synergistically with
collagenases by degrading denatured collagens (gelatins). The stromelysins including
MMP-3 have broader specificity and can degrade non-triple helical regions of native
collagen II, III, IV, V, IX, X, XI and proforms of MMPs as well as proteoglycans and
matrix glycoproteins. Other MMPs not in these groups include matrilysin, metalloelastase and membrane-bound metalloproteinase (MT-MMPs).
MMPs are secreted in a latent pro-enzyme form, their activation involves the loss
of the propeptide. The proteolytic activity of MMPs is under control of several factors
including endogenous specific inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs). The balance between tissue inhibitors of metalloproteinases TIMPs and
activated MMPs affects the ECM remodeling and tissue breakdown in periodontitis.
TIMP-1, a 30-kDa glycoprotein is considered the major inhibitor while TIMP-2 a nonglycosylated inhibitor, though less abundant, binds to pro-MMP-2 and is involved in
controlling its activation.26 In gingival crevicular fluid of patients with periodontitis
TIMP-1 and TIMP-2 levels were found to be lower than in healthy control subjects.27
The expression of MMPs may be upregulated in some pathological conditions
such as inflammation and tumor invasion. In the context of oral diseases, MMPs have
other significant roles in wound healing and immunity and in fibrosis.28,29,30,31 The role
that has been considered of great clinical importance in periodontitis is the ability of
MMPs to activate latent forms of effector proteins, such as antimicrobial peptides,
chemokines, and cytokines, as well their role in altering protein function, such as
shedding of cell-surface proteins.32 During wound healing and inflammation a great
number of chemokines are proteolytically processed by various MMPs which leads to
subsequent modifications of chemokine function. MMP-2 and MMP-9 (also known as
72kDa and 92kDa type IV collagenases or gelatinase A and gelatinase B, respectively)
are known to be upregulated in periodontitis patients.33,34,35 MMP-2 and MMP-9 are also
associated with the malignant phenotype of tumor cells due to their ability to degrade
type IV collagen, a major component of basement membranes.36 Elevated MMP-2 and
MMP-9 activities are important in metastatic cancers such as ovarian carcinoma and oral
cancers.37,38, 39
Current literature searches show no published studies on the effects of METH on
specific oral tissue cells and their activities. A recent study showed that repeated METH
treatment induced behavioral sensitization, which was accompanied by an increase in
MMP-2/-9/TIMP-2 activity in the brain.40 However the effect of METH on gingival
fibroblast MMP production, activity and regulation are unknown. Up-regulation of
gingival fibroblast MMP activity by METH could contribute to the severity of
periodontal destruction and/or tumor metastasis in METH users. In addition, cytotoxic
effects of METH on gingival fibroblasts could compromise the ability of these cells to
repair damaged periodontal tissue.
4

The overall purpose of this project was to examine the effects of METH on
human gingival fibroblasts. The hypothesis tested was that METH contributes to
gingival and periodontal breakdown via cytotoxic effects on gingival fibroblasts and by
altering the balance between MMPs and TIMPS, specifically by increasing the amounts
and/or activity of MMP-2 and/or MMP-9, and by decreasing the levels of TIMP-1 and/or
TIMP-2.
The hypothesis was tested by accomplishing the following specific aims:
Specific Aim 1: Measure constitutive enzyme activity and production of MMP-2
and MMP-9; TIMP-1 and TIMP-2; and MMP:TIMP complexes by human
gingival fibroblasts in vitro.
Specific Aim 2: Measure the effect of METH on cell viability, enzyme activity
and on production of MMP-2, MMP-9, TIMP-1, TIMP-2 and MMP:TIMP
complexes by human gingival fibroblasts in vitro.

5

CHAPTER 2. MATERIALS AND METHODS
Human Gingival Fibroblasts
Normal human gingival fibroblast cell lines, previously established and available
for the study, were used in this work. The cell lines were established from gingival
explants using standard techniques. The gingival explants were minced using a scalpel
and then washed with Dulbecco’s Modified Eagle Medium (DMEM; Gibco; Grant Island,
NY) supplemented with 10% (v/v) newborn calf serum (NCS; Gibco) and 100 g/ml
gentamicin (Sigma Chemical Co.; St Louis, MO) (complete medium), supplemented with
2.5 g/ml amphotericin B (Sigma), 100 U/ml penicillin (Sigma) and 100 g/ml
streptomycin. The tissue pieces were placed in 25 cm2 flasks, allowed to adhere, and then
incubated in complete medium at 37oC in a humidified atmosphere of 5% CO2 in air until
outgrowth of fibroblasts occurred (within two weeks). At the point of confluency in the
25 cm2 flasks, the cells were removed from the flasks by a brief (5 min) treatment with
trypsin (0.25%; Gibco), transferred to 75 cm2 flasks, and routinely cultured in complete
medium. Cells between passages five and fourteen were used in the experiments.
Methamphetamine
Methamphetamine HCl solution [1 mg/ml (5.4x10-3 M) in methanol] and
methamphetamine hydrochloride powder were purchased from Sigma.
Methamphetamine hydrochloride powder is soluble in water.
Determination of Cytotoxic Effects of Methamphetamine on Human Gingival
Fibroblasts
In order to determine the proper, non-cytotoxic doses of METH for experimental
use, the effects of the drug on cell viability were measured. This was assessed by
determining its effect on the ability of the cells to cleave the tetrazolium salt (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) (MTT) to a formazan dye, using
a kit from Boehringer Mannheim Corp. (Indianapolis, IN). Individual wells of 96-well
microtiter tissue culture plates were seeded with 2.5x104 cells in 0.2 ml of complete
medium. The cells were incubated overnight at 37°C. The medium was then removed and
replaced with DMEM containing 100µg/ml gentamicin( DMEM-gent ± METH (25 mM
to 1x10-12 M). 100x METH stock solutions were made in methanol [or water for higher
concentrations to which the cells were exposed (>5x10-5M)] and then diluted 1:100 in
tissue culture medium. It has been determined in this laboratory that methanol at 1% is
not toxic to gingival fibroblasts. After 6 days, MTT was added to the cells at a final
concentration of 0.5 mg/ml and incubated for 4 hr at 37°C. Purple formazan crystals
produced from the MTT by metabolically active cells were solubilized by overnight
exposure to a solubilization solution provided in the kit, at 37°C. Absorbance was read at
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540 nm using a microtiter plate spectrophotometer. Results were expressed as % control
(A540nm in cells exposed to DMEM-gent only).
Determination of MMP and TIMP Production and MMP Activity
To obtain conditioned media for the assays, cells (7.5x104/well in 24-well plates)
were exposed to serum-free (SF) DMEM-gent or SF DMEM-gent containing METH
(1x10-3 M – 1x10-6 M). 100x METH stock solutions were made in methanol [or water for
higher concentrations to which the cells were exposed (>5x10-5M)] and then diluted
1:100 in DMEM-gent. Cell supernatant fluids were harvested at days 1-6. Production of
MMP and TIMP protein was measured in these samples using enzyme-linked
immunosorbent assay (ELISA) kits from R&D Systems (Minneapolis MN). Protein
levels of MMP-2 or MMP-9 complexed with TIMP-1 or TIMP-2 were measured using
specific ELISA (R&D). For the ELISAs, absorbance values were read at using a
microtiter plate spectrophotometer, and the results were expressed as the amount of
protein or activity per mg protein in the conditioned media or in the cell monolayer.41,42
Activity of MMP-2 was measured using the MMP-2 Biotrak Activity Assay
System (GE Healthcare; Piscataway NJ). The assay uses the pro form of a detection
enzyme that can be activated by captured active MMP-2, into an active detection
enzyme, through a single proteolytic event. The natural activation sequence in the pro
detection enzyme has been replaced using protein engineering, with an artificial sequence
recognized by specific matrix metalloproteinases. MMP-activated detection enzyme can
then be measured using a specific chromogenic peptide substrate. Standards and samples
were incubated in microplate wells precoated with anti-MMP-2 antibody. Any MMP-2
present bound to the wells, other components of the sample being removed by washing
and aspiration. Either the endogenous levels of active MMP-2, or the total levels of
MMP-2 in a sample, were detected. In order to measure the total MMP-2 content
(endogenous active + pro-MMP-2), any bound MMP-2 in its pro form is activated using
p-aminophenylmercuric acetate (APMA). The standard is pro MMP-2 which is activated
in parallel for both types of sample. Endogenous active MMP-2 was detected in samples
without APMA treatment. The level of pro-MMP-2 activity was determined by
subtraction (total activity – endogenous activity). Color development was read at 405 nm
in a microplate spectrophotometer. MMP-2 activity is directly proportional to the
generation of color through the cleavage of the substrate used in this kit, it can be
represented by the rate of change of absorbance at 405 nm. i.e δAbs405/h2 x 1000, where h
is the incubation time in hours.
Determination of Direct Effect of METH ± APMA on pro-MMP-2 Activation
In these assays, the pro-MMP-2 standard (6 ng/ml solution) was used. Samples
were incubated with or without APMA, or with METH (1 x 10-6 M – 2.5mM) ± APMA.
The MMP-2 Biotrak Activity Assay System was used to assess effects of these treatments
on activation of pro-MMP-2, as described above.
7

Statistical Analysis
All experiments were performed with triplicate samples. The data were expressed
as mean ± standard deviation and were analyzed using a one-way analysis of variance
(ANOVA) and Scheffe’s F procedure for post hoc comparisons, using StatView®
software.
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CHAPTER 3. RESULTS
Cytotoxic Effects of METH on Human Gingival Fibroblasts
Cytotoxic effects of METH on the fibroblasts were determined using the MTT
assay, which measures the ability of the cells to cleave the tetrazolium salt MTT to a
formazan dye. The results were expressed as percent of control (A540 in cells exposed to
DMEM-gent containing 1% methanol). Previous work showed that 1% methanol is not
toxic to these gingival fibroblasts (data not shown). Figure 2 shows that there was no
significant cytotoxicity of METH at concentrations ≤ 1mM after 6-day exposure.
Concentrations of METH > 1mM caused complete loss of viability.
Constitutive Production of MMPs, TIMPs, and MMP:TIMP Complexes
In initial experiments, the cells were exposed to DMEM-gent containing 1%
methanol (diluent for [METH] ≤ 1 x 10-5 M) for incubation times of 1, 2, 3, 4, and 6 days.
[Preliminary experiments showed that 1% methanol had no effect on cell viability or
production of MMPs or TIMPs (data not shown)]. Figures 3 and 4 show that there was a
time-dependent increase in constitutive production of all molecules assayed (except
MMP-9 and MMP-9/TIMP complexes, which were not expressed). TIMP-1 was
produced in greater amounts than TIMP-2 (Figure 3). Figure 4 shows that MMP-2:TIMP
complexes were produced constitutively (2:2 > 2:1). Approximately 25% MMP-2 was
complexed with TIMP-1 or TIMP-2 under these conditions (data not shown).
Effect of METH on MMP, TIMP, and MMP-TIMP Complex Protein
In experiments testing the effects of METH on the production of MMPs, TIMPs,
and MMP:TIMP complexes, a 4-day incubation period was used, based on the
experiments described above. Figure 5 shows that there was no significant effect of
METH on levels of MMP-2, TIMP-1 or TIMP-2. Similarly, METH had no effect on
MMP-2:TIMP complexes, and exposure to METH did not induce the fibroblasts to
produce detectable protein levels of MMP-9 or MMP-9/TIMP complexes (Figures 5 and
6). There was no significant effect of METH on the percent of MMP-2 complexed with
TIMP-1 or TIMP-2 (Figure 7).
Effects of METH on MMP-2 Activity
Figure 8 shows constitutive levels of total MMP-2 activity, and the effects of
METH. METH (1x10-5 M) significantly increased total (endogenous active + APMAactivated) MMP-2 activity. At this concentration total MMP-2 activity was increased
~50%, compared to control (p = 0.01). When exposed to 1x10-4 M METH, there was a
decrease in total activity of ~25% (p = 0.02).
9

Figure 2. Effect of METH on Gingival Fibroblast Viability
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METH (1x10-5 M) significantly increased APMA-activated MMP-2 activity
attributable to pro-MMP-2 (p = 0.03) (Figure 9). When exposed to 1x10-4 M METH,
there was a decrease in APMA-activated MMP-2 activity attributable to pro-MMP-2 that
was not statistically significant. There was little or no effect of METH on endogenous
active ?MMP-2 (Figure 9).
Direct Effect of METH on MMP-2 Activation and APMA-mediated Activation
Total MMP-2 protein (as well as TIMPS, MMP/TIMP complexes and %
complexed MMP-2) were not significantly affected by METH, yet MMP-2 activity was
increased by exposure to METH. In order to determine whether METH directly activated
MMP-2 or enhanced APMA activation, pro-MMP-2 (6 ng/ml standard from MMP-2
activity kit) was treated with METH ± APMA and assayed for activity. Figure 10 shows
that METH may directly activate MMP-2 and enhance APMA activation of free proMMP-2.
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CHAPTER 4. DISCUSSION
Previous case reports of the adverse effects of METH on oral tissues have
principally focused on teeth. This study attempted to determine the effects of this drug
on soft tissue (gingiva) at the cellular level, specifically the production and activity of
two MMPs that play a role in both periodontal destruction and tumor invasion.
Using an assay that measured the ability of the cells to cleave a tetrazolium salt
MTT to a formazan dye, it was found that concentrations of METH ≤ 1 mM caused no
cytotoxicity to human gingival fibroblasts after 144 hours of exposure. METH at > 1
mM caused complete toxicity and cell death. This is consistent with the results of studies
using other cell types. Israeli et al. found that METH ≥ 1 mM was toxic to mouse
monoaminergic cells, and Deng et al. showed that 2 mM METH killed a minimum of
50% of rat striatal cells after 24-hr exposure.43,44 Another study by Genc et al. found that
METH > 0.1 mM was toxic to rat oligodendrocytes (the myelin-forming cells in the
central nervous system), and that by 72 hr, toxic METH concentrations caused 90% cell
death.45 Oligodendrocytes were therefore somewhat more sensitive to METH than the
human gingival fibroblasts used in the present study. Another study from this laboratory
suggested that the human monocyte cell line THP-1 is also more sensitive to METH than
human gingival fibroblasts.46 Only one METH exposure period (144 hr) was tested in this
study, but the finding that there was >90% toxicity caused by METH concentrations > 1
mM is consistent with the study by Genc et al., cited above. While METH levels in
humans have been measured in plasma and saliva at 0.2 µM and 2 µM, respectively,
because of METH’s high bioavailability and low protein-binding characteristics, peak
drug levels may reach high µM to low mM concentrations.16,47 METH levels in gingival
tissue, however, are not yet known.
Most studies investigating METH cytotoxicity have been performed using
neuronal cells, and it has been suggested that METH-induced release of dopamine from
vesicles to cytosolic and extracellular spaces, with resultant free radical formation, may
be an important factor in METH-induced neurotoxicity.45 However, METH may cause
toxicity independent of dopamine and have a more general toxic process. Results of in
vitro and in vivo experiments suggested that METH can cause apoptotic neuronal cell
death.44,45,48,49,50,51,52,53,54 For example, Genc et al., in work using rat oligodendrocytes,
suggested that METH upregulated the pro-apoptotic genes bax and DP5, and studies by
Israeli et al. showed that METH neurotoxicity involves a p53-inducible gene that
promotes apoptosis.43,45 Other studies have suggested roles for superoxide radicals,
cytokines, caspase activation, or temperature in METH cytotoxicity.55,56,57, 58,59, 60, 61
The specific mechanism(s) of METH-induced cytotoxicity in gingival fibroblasts
are unknown and await further study. It is likely that complex interactions between cells
and other factors which affect cell behavior, such as extracellular matrix composition,
may be involved in METH cytotoxicity in vivo. However, toxic effects of METH on
human gingival fibroblasts, as shown in the present study, could compromise their
synthetic ability and their involvement in periodontal healing, after the tissue destruction
associated with chronic inflammation.
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In this study the effects of METH on matrix metalloproteinases (MMPs) were
studied. MMPs comprise a large family of proteolytic enzymes containing a zinc-binding
catalytic domain and act to degrade components of the extracellular matrix.62,63 The
expression of different MMPs may be upregulated in pathological conditions such as
inflammation and tumor invasion. In the context of oral diseases, MMPs are suggested to
play an important role in the tissue destruction caused by the chronic inflammation of
periodontitis.64 MMP amounts and activities are significantly higher in gingival tissue
and gingival crevicular fluid of periodontitis patients than in healthy subjects, and
elevated MMP activity can also contribute to the metastasis of oral cancer.26,65,66 Ongoing
elevated production/activity of MMPs by tumor and tumor-associated cells, and by host
cells following stimulation by periodontopathogens, contributes to tissue destruction in
these diseases.62 For example, MMP-2 and MMP-9 (also known as 72kDa and 92kDa
type IV collagenases or gelatinase A and gelatinase B, respectively) are upregulated in
periodontitis patients.67,68,69 The gelatinases can cleave several substrates, including
collagen types IV and V, laminin, and chondroitin sulfate proteoglycan. MMP-2 and
MMP-9 are also associated with the malignant phenotype of tumor cells due to their
ability to degrade type IV collagen which is a major component of basement
membranes.70 These MMPs are localized to the leading edges during normal and
neoplastic cell invasion and migration and are believed to play a critical role in tumor
invasiveness and metastasis.71 For example, elevated MMP-2 and MMP-9 activities have
been shown to be important in metastatic cancers such as ovarian carcinoma and oral
cancers.26,72,73,74
In health, MMPs are involved in normal remodeling and turnover of periodontal
tissues.
MMP expression and activity are tightly regulated and are subject to several
layers of control in transcription and post-translational activation.75 For example, most
MMPs are secreted in latent form. The exact activation mechanisms of these MMP
proenzymes are not well understood. In vitro, pro-MMPs are activated by treatment with
proteinases, mercurial compounds, chaotropic agents, HOCl, low pH, or heat.76,77,78,79, 80
In vivo, activation may occur through cleavage by other MMPs or by serine proteases
such as trypsin or plasmin.81,82 In addition, MMP activity is regulated by endogenous
specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), and the tissue
plasminogen/plasmin system.62,63,83,84 The balance between MMPs and TIMPs plays an
important role in maintaining the integrity of healthy tissues. Together, MMPs and
TIMPs modulate functional and structural remodeling of the cellular milieu through
cleavage of extracellular matrix (ECM) molecules, bioavailability of growth factors and
cytokines, and shedding of membrane receptors.85,86,87 A disturbed balance of MMPs and
TIMPs can be found in various pathologic conditions.88,89,90 Four closely-related TIMPs
have been discovered in different species, designated TIMP-1, -2, -3, and -4.91,92,93,94,95 In
the ECM, TIMPs form non-covalent 1:1 stoichiometric complexes with MMPs. Almost
all MMPs can be inhibited by all four TIMPs, although differences in binding affinity
have been reported.96 MMPs are produced by the major cell types in human periodontal
tissue, including neutrophils, macrophages, epithelial cells, and fibroblasts.97 Fibroblasts
are a major constituent of the gingival connective tissue. They produce structural
62,63
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connective tissue proteins and glycosaminoglycans, cytokines and mediators that promote
chronic inflammation, as well as MMPs and TIMPs.98,99
In this study, the effects of METH on human gingival fibroblast production of
MMP-2 and MMP-9, TIMP-1 and TIMP-2, and MMP:TIMP complexes were
determined. The fibroblasts constitutively produced MMP-2, TIMP-1, and TIMP-2.
MMP-9 was not constitutively produced by these cells. These findings are consistent with
the observation that human gingival fibroblasts used in another study produced MMP-2,
TIMP-1, and TIMP-2, but not MMP-9.100 While a study by Westerlund et al. showed that
neutrophils were the major source of MMP-9 in periodontitis gingiva, others found that
rat gingival fibroblasts produce MMP-9 constitutively, and in response to stimulation by
TNFα.101,102 MMP-9 can also be produced by human and mouse dermal and lung
fibroblasts, constitutively or in response to factors such as mast cell interaction, tumor
cell interaction (via TNFα, TGF and EGF) and thrombin.103,104,105,106 When expressed by
fibroblasts, MMP-9 levels are usually low, compared to MMP-2.107 MMP-2/TIMP
complexes were produced constitutively (MMP-2:TIMP-2 > MMP-2:TIMP-1). While
there was no detectable MMP-9 production, the possibility existed that MMP-9 might be
present in TIMP complexes that were not recognized by the MMP-9 assay, which has no
cross-reactivity with TIMPs 1-4. However, there was no detectable constitutive
production of MMP-9:TIMP-1 or MMP-9:TIMP-2 complexes. Approximately 25%
constitutively-produced MMP-2 was complexed with TIMP-1 orTIMP-2 under these
conditions, as measured with these ELISA systems.
There was no significant effect of METH on MMP-2, TIMP-1, TIMP-2, or MMP2:TIMP complex protein levels, and METH had no significant effect on % complexed
MMP-2 protein. Exposure to METH also did not induce detectable levels of MMP-9 or
MMP-9/TIMP complexes. The lack of effect of METH on amounts of MMP-2 and
TIMP-2 produced by the cells used in this study is in contrast to studies by Mizoguchi et
al. on the effects of METH on rat neural tissue.40,108 They reported that repeated METH
treatment increased MMP-2 levels in rat brain frontal cortex and nucleus accumbens, as
well as MMP-9 levels and activity. MMP-2 and -9 expression induced by METH in these
tissues was localized to neuronal and glial cells. Repeated METH treatment also
increased TIMP-2 levels in rat brain frontal cortex, localized to neuronal cells.
In addition to MMP-2 protein, the effects of METH on MMP-2 activity were also
determined. The assay used in this study detected endogenous levels of active MMP-2,
or the total levels of MMP-2 (endogenous active + pro-MMP-2). In order to measure the
total MMP-2 content, MMP-2 in its inactive pro form was activated using paminophenylmercuric acetate (APMA). Endogenous active MMP-2 (i.e. MMP-2
secreted in the active form) was detected in samples without APMA treatment. METH at
1x10-5 M increased total (endogenous active + APMA-activated) MMP-2 activity by
approximately 50%, compared to control, and significantly increased APMA-activated
MMP-2 activity attributable to pro-MMP-2. This is consistent with another study which
showed that repeated METH administration increased MMP-2 activity in rat brain,
attributable to pro-MMP-2 and did not increase endogenous MMP-2 activity.40 In the
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present study, while there were low levels (generally <10%) of detectable endogenous
active MMP-2, METH had no effect on this.
Total MMP-2 protein as well as TIMPS, MMP/TIMP complexes and %
complexed MMP-2) were not significantly affected by METH, yet MMP-2 activity was
increased by exposure to 1x10-5 M METH. This suggested that METH may affect MMP2 post-transcriptionally, perhaps increasing activation of pro-MMP-2, rather than
affecting MMP-2 protein levels. Because METH did not significantly affect TIMPs,
MMP/TIMP complexes and % complexed MMP-2, the increased activity was likely not
due to changes in the levels of MMP inhibitors. (As noted above, the lack of effect of
METH on gingival fibroblast TIMP-2 production is in contrast to its stimulation of rat
neuronal TIMP-2).40 Therefore, the question was asked whether METH directly affected
MMP-2 activation. In order to determine whether METH directly activated MMP-2 or
enhanced APMA activation, pro-MMP-2 (standard from MMP-2 activity kit) was treated
with METH ± APMA and assayed for activity. The results suggested that METH may
directly activate MMP-2 and enhance APMA activation of free pro-MMP-2.
Itoh et al. have investigated the mechanism of activation of pro-MMP-2 by
APMA.109 Pro-MMP-2 consists of a propeptide domain, a catalytic domain, and a Cterminal domain.110 Latency of pro-MMP-2 is maintained through the co-ordination of
the Zn atom at the active site and the SH group of the cysteine residue in a highly
conserved sequence of the propeptide domain.76,77 Pro-MMP-2 is readily activated in
vitro by APMA. Itoh et al. have suggested that APMA perturbs the pro-MMP-2
molecule, as they showed for the activation of pro-MMP-3.111 The conformational
changes in pro-MMP-2 subsequently disrupt the Cys-Zn interaction and exposes the
active site.
Only free (non-TIMP-complexed) pro-MMP-2 expresses full activity upon
activation by APMA. However, formation of the pro-MMP-2-TIMP-2 complex does not
prevent its partial activation by APMA; the activated complex has enzymic activity
equivalent to approximately 10% of free MMP-2.111,112,113,114,115,116 Among the MMPs,
pro-MMP-2 is unique in its ability to bind TIMPS. All other MMPs must be in their
active form to bind TIMPs.117
In their investigation of the mechanism of activation of pro-MMP-2 by APMA,
Itoh et al. used isolated pro-MMP-2-TIMP-2 complexes. They showed that treatment of
this complex with APMA rearranges the interaction between TIMP-2 and pro-MMP-2
and that the N-terminal domain of TIMP-2 reacts with the catalytic site of pro-MMP-2
(Figure 11). Because the active site is then tightly blocked by TIMP, this complex
remains proteolytically inactive. Addition of active MMP-2 or MMP-3 can cleave the
propeptde, but the complex remains inactive . On the other hand, addition of an active
MMP such as MMP-2 or MMP-3 to the pro-MMP-2-TIMP-2 complex (before addition of
APMA) can bind and block the N-terminal domain of the TIMP-2 molecule that is bound
to pro-MMP-2, forming a ternary complex. Subsequent addition of APMA causes
conformational changes that break the Zn-Cys interaction. The ternary complex is
proteolytically active because N-terminal domain of TIMP has been previously blocked
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Figure 11. Proposed Mechanism of Activation of the Pro-MMP-2:TIMP-2
Complex by APMA
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(by the added, active MMP) and cannot bind to the active site of the pro-MMP-2
molecule (Figure 11). The level of MMP-2 activity attained depends upon the amount of
active MMP-2 added prior to the addition of APMA. Therefore, Itoh et al. have shown
that the level of active MMPs can influence MMP-2 activity.109
Our results show that METH can directly increase enzymatic activity of active
MMP-2, and can also potentiate activation of pro-MMP-2 by APMA. The mechanisms
for these effects remain to be investigated. A possible mechanism for direct increase in
activity of active MMP-2 could be a METH-induced conformational change in MMP-2
that affects the active site and increases activity. It has been suggested that METH may
cause a conformational change in another protein, vesicular monoamine transporter-2, in
rats.118 In a similar vein, METH may also potentiate the conformational perturbations
caused by APMA, or interact with and make the Zn-Cys interaction of pro-MMP-2 less
stable, resulting in increased activity. While this may at least partially account for the
METH-induced increase in MMP-2 activity in cell culture supernatants, it remains to be
investigated. A recent search of the literature revealed no information on the ability of
METH to directly disrupt the interaction of Zn2+ with other molecules.
As noted above, Itoh et al. have shown that the levels of other active MMPs can
influence MMP-2 activity. In the present study, METH caused some increase in MMP-1
at 1 x 10-5 M and 1 x 10-6 M, but these increases were not statistically significant (data
not shown). [MMP-2 activity was increased at METH concentrations ≥ 5 x 10-5 M
(statistically significant at 1 x 10-5 M only)]. METH was shown by others to increase
MMP-1 production by mixed human neuron/astrocyte cultures.119 We found that METH
also increased MMP-3 levels, but at concentrations higher than which an effect was seen
on MMP-2 activity (≥ 1 x 10-4 M) (data not shown). This suggests that METH could
increase MMP-2 activity of gingival fibroblasts by increasing MMP-1, or possibly MMP3 levels, but this remains to be shown.
Another question remaining is the influence of the tissue plasminogen/plasmin
system. In vivo, plasminogen activators, including urokinase-type plasminogen activator
(uPA) and tissue plasminogen activator (tPA), convert plasminogen into plasmin, which
then converts latent MMPs into their active forms (Vassalli et al.,1991).120 Interestingly,
Xiao et al. reported that tPA levels in gingival crevicular fluid are correlated with the
severity of periodontal conditions, suggesting that the plasminogen activator system plays
a significant role in connective tissue destruction.121 METH was shown to increase uPA
in human brain cells, but this is unknown for gingival fibroblasts.112
Generally, Pro-MMP-2 is resistant to activation by serine proteases alone, and in
vivo, MMP-2 activation is mediated by membrane bound MMP (MT-MMP).112,122 In this
instance, pro-MMP-2 activation by MT1-MMP (MMP-14) depends on low levels of
TIMP-2, which binds to pro-MMP-2 and forms a ternary complex with MT1-MMP.71
Another MT-MMP then cleaves the bound MMP-2 and activates it. High concentrations
of TIMP-2 can prevent pro-MMP-2 activation because it inhibits MT1-MMP.
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Most MT-MMPs (MT1-, MT2-, MT3-, MT5-, and MT6-MMPs) can also activate
pro-MMP-2. Several serine proteases can act in concert with MT1-MMP to activate proMMP-2.123 However, work by others has suggested that pro-MMP-2 can be activated
independently of MT-MMP. Tiranathanagul T et al. showed that bacterial LPS can
activate pro-MMP-2 via a serine protease dependent pathway in periodontal ligament
cells and human breast adenocarcinoma cells124 and Nguyen et al. showed that activated
protein C directly activated pro-MMP-2 in endotherial cells.125 In addition, latent MT1MMP can be shed from the cell membrane, activated via the uPA cascade, leading to
activation of pro-MMP-2.126
The work in the present study has shown that METH can increase MMP-2
activity in vitro. METH did not affect protein levels of MMP-2 or its inhibitors TIMP-1
or TIMP-2. However, we showed that METH can increase the activity of active MMP-2,
and potentiate APMA-activation of pro-MMP-2. This may occur through METH-induced
conformational perturbations or disruption of the Zn-Cys interaction important in
maintaining the latency of this enzyme, as well as the increase in other MMPs that can
help activate pro-MMP-2. In vivo, METH may be able to have similar actions on proMMP-2 activation, but other factors could contribute to its activation. These include
plasminogen activators well as MT-MMPs.
As mentioned earlier current literature show no published studies on the effects of
METH on specific oral tissue cells and their activities. The effect of METH on gingival
fibroblast MMP production, activity and regulation were unknown. Up-regulation of
MMP-2 activity in vitro by METH on gingival fibroblast is an interesting finding.
Whether this effect can be seen in vivo as well is a subject for future studies. However
this highlights the possible role of METH in vitro in increasing the severity of periodontal
destruction and tumor metastasis. It also raises questions about the mechanisms that
might be at play when METH comes into contact with oral tissue cells. Further studies
would be needed to explain their mechanisms and to understand how this drug might be
complicating and contributing to oral tissue destruction when tissues are inflamed as in
chronic periodontal disease.
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